Selective inhibitors of plasmepsin II of Plasmodium falciparum on the basis of pepstatin
暂无分享,去创建一个
A. G. Mikhailova | L. Rumsh | I. Mikhura | E. E. Mel’nikov | I. Prudchenko | I. Mikhaleva | A. Formanovskii | E. Kaliberda | N. I. Dergousova | L. Chikin
[1] Jun Liu,et al. Hemoglobin-degrading Plasmepsin II Is Active as a Monomer* , 2006, Journal of Biological Chemistry.
[2] L. Prade,et al. X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor* , 2005, Journal of Biological Chemistry.
[3] Jun Liu,et al. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Goldberg,et al. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. , 2001, Trends in parasitology.
[5] I. Gluzman,et al. Naturally‐occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium f alciparum , 1999, FEBS letters.
[6] D. Goldberg,et al. Biosynthesis and Maturation of the Malaria Aspartic Hemoglobinases Plasmepsins I and II* , 1997, The Journal of Biological Chemistry.
[7] B. Dunn,et al. High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum , 1994, FEBS letters.
[8] I. Gluzman,et al. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. , 1994, The Journal of clinical investigation.
[9] R E Cachau,et al. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] I. Gluzman,et al. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. , 1994, The EMBO journal.
[11] B. Chait,et al. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease , 1991, The Journal of experimental medicine.
[12] D. Goldberg,et al. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[13] Marvin J Miller,et al. Mycobactins: synthesis of (-)-cobactin T from .epsilon.-hydroxynorleucine , 1981 .
[14] V. Mutt,et al. Cholecystokinin (pancreozymin). 4. Synthesis and properties of a biologically active analogue of the C-terminal heptapeptide with epsilon-hydroxynorleucine sulfate replacing tyrosine sulfate. , 1978, Journal of medicinal chemistry.
[15] B. Gisin. The Preparation of Merrifield‐Resins Through Total Esterification With Cesium Salts , 1973 .
[16] P. Henderson,et al. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. , 1972, The Biochemical journal.
[17] L. S. Harrow. Organic Syntheses, Collective , 1955 .
[18] Howard L. Saft,et al. Active site specificity of plasmepsin II , 1999, Protein science : a publication of the Protein Society.
[19] B. Dunn,et al. Plasmepsins I and II from the malarial parasite Plasmodium falciparum. , 1998, Advances in experimental medicine and biology.
[20] D. Goldberg. Hemoglobin degradation in the malaria parasite : an ordered process in a unique organelle , 1990 .
[21] J. Baldwin,et al. Synthesis of n-benzyloxycarbonyl-l-α-aminoadipic acid, α-benzyl ester , 1988 .
[22] D. Grobelny. A new method of synthesis of -haloethylbenzyl ethers , 1979 .